Skip to content

Study · Animal study (in vivo) · mouse · 1984

11 results

Effect of prolyl-leucyl-glycinamide and alpha-melanocyte-stimulating hormone on levorphanol-induced analgesia, tolerance and dependence.

Contreras PC, Takemori AE

Life sciences1 Jun 1984Cited by 16 (Europe PMC)

PMID6146083 (opens in a new tab)DOI10.1016/0024-3205(84)90041-9 (opens in a new tab)PepBankPUB-06146083
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice, low-dose PLG did not affect levorphanol analgesia.

    In plain wordsIn mice, low-dose PLG did not change pain relief from levorphanol.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    No significant changeLevorphanol analgesia at low PLG dose
    Study

    mousen: not reported in source

    Levorphanol-exposed mice
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    10 ng/mouse · intracerebroventricularAs given in this study (mouse).

    Source sentences

    Summary
    Prolyl-leucyl-glycinamide (PLG) at a low dose (10 ng/mouse) administered by an intracerebroventricular (i.c.v.) injection did not affect levorphanol analgesia,
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice, PLG antagonized levorphanol analgesia at the intermediate dose.

    In plain wordsIn mice, intermediate-dose PLG reduced pain relief from levorphanol.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    DecreaseLevorphanol analgesia at intermediate PLG dose
    Study

    mousen: not reported in source

    Levorphanol-exposed mice
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    10 micrograms/mouse · intracerebroventricularAs given in this study (mouse).

    Source sentences

    Summary
    but PLG at higher doses (10 and 100 micrograms/mouse) and alpha-melanocyte-stimulating hormone (alpha-MSH) (10 ng/mouse) antagonized levorphanol analgesia.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice, high-dose PLG antagonized levorphanol analgesia.

    In plain wordsIn mice, high-dose PLG reduced pain relief from levorphanol.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    DecreaseLevorphanol analgesia at high PLG dose
    Study

    mousen: not reported in source

    Levorphanol-exposed mice
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    100 micrograms/mouse · intracerebroventricularAs given in this study (mouse).

    Source sentences

    Summary
    but PLG at higher doses (10 and 100 micrograms/mouse) and alpha-melanocyte-stimulating hormone (alpha-MSH) (10 ng/mouse) antagonized levorphanol analgesia.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice, low-dose PLG facilitated development of levorphanol tolerance.

    In plain wordsIn mice, low-dose PLG increased development of tolerance to levorphanol.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    IncreaseLevorphanol tolerance at low PLG dose
    Study

    mousen: not reported in source

    Levorphanol-exposed mice
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    10 ng/mouse · intracerebroventricularAs given in this study (mouse).

    Source sentences

    Summary
    Development of levorphanol tolerance was facilitated by 10 ng/mouse of PLG, unaffected by 10 micrograms/mouse of PLG, but antagonized by 100 micrograms/mouse of PLG and 10 ng/mouse of alpha-MSH.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mice, intermediate-dose PLG did not affect development of levorphanol tolerance.

    In plain wordsIn mice, intermediate-dose PLG did not change development of tolerance to levorphanol.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    No significant changeLevorphanol tolerance at intermediate PLG dose
    Study

    mousen: not reported in source

    Levorphanol-exposed mice
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    10 micrograms/mouse · intracerebroventricularAs given in this study (mouse).

    Source sentences

    Summary
    Development of levorphanol tolerance was facilitated by 10 ng/mouse of PLG, unaffected by 10 micrograms/mouse of PLG, but antagonized by 100 micrograms/mouse of PLG and 10 ng/mouse of alpha-MSH.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In mice, high-dose PLG antagonized development of levorphanol tolerance.

    In plain wordsIn mice, high-dose PLG reduced development of tolerance to levorphanol.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    DecreaseLevorphanol tolerance at high PLG dose
    Study

    mousen: not reported in source

    Levorphanol-exposed mice
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    100 micrograms/mouse · intracerebroventricularAs given in this study (mouse).

    Source sentences

    Summary
    Development of levorphanol tolerance was facilitated by 10 ng/mouse of PLG, unaffected by 10 micrograms/mouse of PLG, but antagonized by 100 micrograms/mouse of PLG and 10 ng/mouse of alpha-MSH.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In mice, low-dose PLG facilitated development of levorphanol dependence.

    In plain wordsIn mice, low-dose PLG increased development of dependence on levorphanol.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    IncreaseLevorphanol dependence at low PLG dose
    Study

    mousen: not reported in source

    Levorphanol-exposed mice
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    10 ng/mouse · intracerebroventricularAs given in this study (mouse).

    Source sentences

    Summary
    PLG (10 ng/mouse) facilitated the development of levorphanol dependence, but 10 micrograms/mouse of PLG had no effect.
    1 context sentence
    Summary · context
    The effect of PLG on levorphanol dependence was assessed by changes in body weight and temperature during naloxone-induced withdrawal.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In mice, intermediate-dose PLG did not affect development of levorphanol dependence.

    In plain wordsIn mice, intermediate-dose PLG did not change development of dependence on levorphanol.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    No significant changeLevorphanol dependence at intermediate PLG dose
    Study

    mousen: not reported in source

    Levorphanol-exposed mice
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    10 micrograms/mouse · intracerebroventricularAs given in this study (mouse).

    Source sentences

    Summary
    PLG (10 ng/mouse) facilitated the development of levorphanol dependence, but 10 micrograms/mouse of PLG had no effect.
    1 context sentence
    Summary · context
    The effect of PLG on levorphanol dependence was assessed by changes in body weight and temperature during naloxone-induced withdrawal.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In mice, high-dose PLG antagonized development of levorphanol dependence.

    In plain wordsIn mice, high-dose PLG reduced development of dependence on levorphanol.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    DecreaseLevorphanol dependence at high PLG dose
    Study

    mousen: not reported in source

    Levorphanol-exposed mice
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    100 micrograms/mouse · intracerebroventricularAs given in this study (mouse).

    Source sentences

    Summary
    PLG (100 micrograms/mouse) antagonized development of levorphanol dependence.
    1 context sentence
    Summary · context
    The effect of PLG on levorphanol dependence was assessed by changes in body weight and temperature during naloxone-induced withdrawal.
  10. 10AnimalAnimal study (in vivo)Safety outcome

    In levorphanol-dependent mice, intermediate-dose PLG precipitated withdrawal.

    In plain wordsIn mice dependent on levorphanol, intermediate-dose PLG triggered withdrawal.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    IncreasePrecipitated levorphanol withdrawal at intermediate PLG dose
    Study

    mousen: not reported in source

    Levorphanol-exposed mice
    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    10 micrograms/mouse · intracerebroventricularAs given in this study (mouse).

    Source sentences

    Summary
    PLG at doses of 10 and 100 micrograms/mouse precipitated withdrawal in levorphanol-dependent mice.
  11. 11AnimalAnimal study (in vivo)Safety outcome

    In levorphanol-dependent mice, high-dose PLG precipitated withdrawal.

    In plain wordsIn mice dependent on levorphanol, high-dose PLG triggered withdrawal.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    IncreasePrecipitated levorphanol withdrawal at high PLG dose
    Study

    mousen: not reported in source

    Levorphanol-exposed mice
    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    100 micrograms/mouse · intracerebroventricularAs given in this study (mouse).

    Source sentences

    Summary
    PLG at doses of 10 and 100 micrograms/mouse precipitated withdrawal in levorphanol-dependent mice.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.